… 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT) --Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than …

… PD-L1 inhibition overcomes T-cell suppression at the tumor; and chemotherapy causes tumor cell death and antigen … molecularly characterized via sequencing of tumor tissue DNA and/or circulating tumor DNA samples. Progression free survival and …

… complex malignancy. Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is … that IASLC is in the forefront in this arena.” Although tumor tissue is historically the gold standard biospecimen … biopsy approach includes a variety of methodologies for circulating analytes. From a clinical point of view, plasma …

… Barcelona— Tumor mutational burden was not significantly associated … Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data … by whole-exome sequencing of tumor and matched normal DNA. The clinical utility of TMB on outcomes was assessed …

… specific cancer’s growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be … EGFR  T790M in relapse may be done by biopsy or cell-free circulating DNA.  However cell-free DNA is not appropriate for initial …

… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …

… Award to Gabriella Sozzi, PhD. Dr. Sozzi leads the Tumor Genomics Unit at Fondazione IRCCS Istituto Nazionale Tumori (INT) in Milan, Italy. She graduated in Biological … of lung cancer in screening programs. In the field of circulating biomarkers, she has a demonstrated record of …